Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference on November 29, 2022, at 11:20 a.m. ET. David M. Reese, M.D., executive vice president of Research and Development, will lead the presentation. The event will be web-streamed and accessible to media, investors, and the public, with archives available for 90 days on Amgen's website. The company focuses on innovative therapeutics for serious health issues, leveraging advanced genetics. Amgen is a leading biotechnology company, featured in the Dow Jones Industrial Average and Nasdaq-100 index.
Amgen presented new analysis data from the Phase 3 FOURIER and FOURIER-OLE studies of Repatha (evolocumab) at the AHA Scientific Sessions 2022. Results indicate that maintaining LDL-C levels below 20 mg/dL correlates with improved cardiovascular outcomes, without new safety signals over up to 8.6 years of follow-up. Notably, 13% of patients achieved these low LDL-C levels, leading to a decreased risk of cardiovascular events like myocardial infarction and stroke. The data supports the role of Repatha in managing atherosclerotic cardiovascular disease (ASCVD) risk.
Amgen (NASDAQ:AMGN) announced new clinical data highlighting the effectiveness of AMGEVITA® (adalimumab) and TAVNEOS® (avacopan) at the upcoming American College of Rheumatology Convergence from Nov. 10-14, 2022. The data will present real-world evidence on treatment satisfaction and persistence of AMGEVITA among German patients with rheumatic diseases. Additionally, TAVNEOS research will focus on renal function recovery in severe active ANCA-associated vasculitis patients. This research showcases Amgen's commitment to innovation in treating inflammatory diseases.
Amgen announced phase 2 clinical trial results for olpasiran, showing over 95% reduction in lipoprotein(a) levels in patients with atherosclerotic cardiovascular disease (ASCVD). Conducted with 281 participants, the trial demonstrated significant efficacy at doses of 75 mg and higher every 12 weeks. Results were shared at the American Heart Association meeting and published in the New England Journal of Medicine. Amgen plans to start a phase 3 trial in December 2022 to further explore olpasiran's potential.
Amgen will present at the Credit Suisse 31st Annual Global Healthcare Conference on November 9, 2022, at 3:50 p.m. ET. Key executives, including David M. Reese, M.D., and Peter H. Griffith, will speak at the event. The presentation will be available via webcast for media, investors, and the public, with an archive accessible for 90 days afterward. Amgen, a leading biotechnology company, focuses on developing innovative therapies for serious illnesses and is included in the Dow Jones Industrial Average. For further details, visit Amgen's investor relations page.
Amgen (NASDAQ:AMGN) reported Q3 2022 financial results with total revenues declining 1% to $6.7 billion, impacted by a 5% drop in net selling prices and 2% loss from foreign exchange, despite 8% growth in sales volume. GAAP EPS rose 20% to $3.98, driven by reduced operating expenses and share buybacks. The company generated $2.8 billion in free cash flow, a 27% increase year-over-year. Amgen revised its 2022 revenue guidance to $26.0-$26.3 billion and EPS guidance to $11.46-$12.17 (GAAP).
On Nov. 2, 2022, Amgen (NASDAQ:AMGN) announced a webcast for investors during the American Heart Association Scientific Sessions at 6:00 p.m. ET on Nov. 7, 2022. The call will feature Dr. David M. Reese and Amgen's R&D team discussing Phase 2 data on olpasiran, aimed at lowering apolipoprotein(a) linked to cardiovascular risks. Updates on a Phase 1 study of AMG 133, for obesity, will also be provided. The webcast will be accessible online, archived for 90 days, and more details can be found on Amgen's website.
Amgen will report its third quarter financial results on November 3, 2022, after U.S. market close, followed by a conference call at 1:30 p.m. PT. CEO Robert A. Bradway and senior management will participate, and the call will be accessible via a live audio stream for the public. Amgen is recognized as one of the leading biotechnology companies, focusing on innovative therapeutics and medical needs. The company is included in the Dow Jones Industrial Average and the Nasdaq-100.
Amgen (NASDAQ:AMGN) has declared a $1.94 per share dividend for Q4 2022, set to be paid on December 8, 2022. Shareholders of record as of November 17, 2022 will be eligible. Amgen continues to focus on innovative therapeutics and has been recognized as one of the world's top biotechnology companies. The company emphasizes its commitment to addressing high unmet medical needs through advanced human genetics and has been acknowledged for its workplace culture and sustainability efforts.
Amgen has completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share, enhancing its inflammation portfolio with TAVNEOS (avacopan), a novel treatment for ANCA-associated vasculitis. TAVNEOS is FDA-approved and addresses a significant unmet medical need in autoimmune disease treatment. The acquisition also includes three early-stage candidates targeting inflammatory diseases and cancer.
